Dr. Reddy's Laboratories Limited (NYSE:RDY) Position Boosted by Sei Investments Co.

Sei Investments Co. boosted its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 399.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,625 shares of the company's stock after purchasing an additional 66,072 shares during the period. Sei Investments Co.'s holdings in Dr. Reddy's Laboratories were worth $1,305,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. lifted its stake in shares of Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after buying an additional 9,373,412 shares in the last quarter. Van ECK Associates Corp grew its holdings in Dr. Reddy's Laboratories by 609.4% during the 4th quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock valued at $92,000 after purchasing an additional 5,015 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Dr. Reddy's Laboratories by 400.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock worth $8,373,000 after buying an additional 427,573 shares during the period. World Investment Advisors LLC purchased a new stake in Dr. Reddy's Laboratories in the 3rd quarter valued at about $3,459,000. Finally, Crossmark Global Holdings Inc. increased its stake in shares of Dr. Reddy's Laboratories by 328.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company's stock valued at $201,000 after buying an additional 9,781 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.

Analysts Set New Price Targets

Separately, Nomura downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.

Dr. Reddy's Laboratories Price Performance

RDY traded up $0.51 during midday trading on Friday, hitting $13.22. 2,756,790 shares of the company traded hands, compared to its average volume of 1,402,091. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 52-week low of $12.26 and a 52-week high of $16.89. The company has a market capitalization of $11.03 billion, a price-to-earnings ratio of 21.04 and a beta of 0.51. The business has a 50 day simple moving average of $13.20 and a two-hundred day simple moving average of $14.36.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, equities analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.